Evidence map›Paper›PMID 36369278›Full record

ArticleCommunications medicine2022

Correlation between structural heart disease and cardiac SARS-CoV-2 manifestations.

Felix Nägele, Michael Graber, Jakob Hirsch, Leo Pölzl, Sabina Sahanic, Manuel Fiegl, Dominik Hau, Clemens Engler, Sophia Lechner, Anna Katharina Stalder and 7 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04416100 (Development of Interstitial Lung Disease), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04416100 unknown statusnot on this map

Development of Interstitial Lung Disease (ILD) in Patients With Severe SARS-CoV-2 Infection

TypeobservationalSponsorMedical University InnsbruckRan2020 to 2022Enrolled130ConditionsCovid-19, Pulmonary FibrosisArmsPulmonary function tests, Imaging, Blood sampling
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. COVID-19 and Diarylamidines: The Parasitic Connection.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 2 countries.

Felix Nägele *Department of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria.ORCID http://orcid.org/0000-0002-9666-341X
Michael Graber *Department of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria.
Jakob HirschDepartment of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria.
Leo PölzlDepartment of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria.
Sabina SahanicDepartment of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
Manuel FieglDepartment of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria.
Dominik HauDepartment of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria.
Clemens EnglerDepartment of Internal Medicine I, Medical University of Innsbruck, Innsbruck, Austria.
Sophia LechnerDepartment of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria.
Anna Katharina StalderInstitute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
Kirsten D MertzInstitute of Pathology, Cantonal Hospital Baselland, Liestal, Switzerland.ORCID http://orcid.org/0000-0002-3074-6925
Jasmin D HaslbauerInstitute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
Alexandar TzankovInstitute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0002-1100-3819
Michael GrimmDepartment of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria.
Ivan TancevskiDepartment of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
Johannes HolfeldDepartment of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria.
Can Gollmann-TepeköylüDepartment of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria. can.gt@i-med.ac.at.
Innsbruck Medical University · ATUniversity Hospital of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prognosis of COVID-19 patients with cardiac involvement is unfavorable and it remains unknown which patients are at risk. The virus enters cells via its receptor angiotensin-converting enzyme 2 (ACE2). Myocardial ACE2 expression is increased in structural heart disease (SHD). We, therefore, aimed to analyze correlations between structural heart disease and cardiac SARS-CoV-2 manifestation.

methodsThe clinical course of COVID-19 in patients with structural heart disease was assessed in a prospective cohort of 152 patients. The primary endpoints consisted of hospitalization and survival. Cardiac tissue of 23 autopsy cases with lethal COVID-19 course was obtained and analyzed for (a) the presence of SHD, (b) myocardial presence of SARS-CoV-2 via RT,-PCR, and (c) levels of ACE2 expression using immunofluorescence staining.

resultsStructural heart disease is found in 67 patients, of whom 56 (83.60%) are hospitalized. The myocardium is positive for SARS-CoV-2 in 15 patients (65%) in 23 autopsy cases of lethal COVID-19. Moreover, most hearts with evidence of myocardial SARS-CoV-2 have structural heart disease [11 (91,67%) vs. 1 (8,33%), p = 0.029]. Myocardial presence of SARS-CoV-2 is correlated with a significant downregulation of ACE2 compared to negative control hearts (6.545 ± 1.1818 A.U. vs. 7.764 ± 2.411 A.U., p = 0.003). The clinical course of patients with cardiac SARS-CoV-2 manifestation is unfavorable, resulting in impaired survival (median, 12 days and 4.5 days, respectively, HR 0.30, 95% CI, 0.13 to 0.73, p = 0.0005)

conclusionsWe provide evidence for a correlation between SHD, altered ACE2 receptor expression, and cardiac SARS-CoV-2 manifestation. Consequently, structural heart disease may be considered a distinct risk factor for a severe clinical course after infection with SARS-CoV-2. REGISTRATION NUMBER LOCAL IRB: Ethics Committee of Northwestern and Central Switzerland ID 2020-00629; Ethics Committee of the Medical University Innsbruck EK Nr: 1103/2020. CLINICALTRIALS: GOV NUMBER: NCT04416100.

Identifiers

PMID36369278
PMCPMC9651888
OpenAlexW4308792159

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.